Simple Predictor In Scleroderma Related Interstitial Lung Disease PDF Print E-mail
Tuesday, 23 October 2012 23:18
Patients at high risk of deterioration or death from Systemic Sclerosis-related interstitial lung disease can be readily spotted using CT scans, suggest Melbourne researchers.

Patients classified as having “extensive” (> 20%) lung disease as seen on an HRCT-lung  scan were three times more likely to die, need supplementary oxygen or a lung transplant, the authors wrote in Rheumatology.

Baseline HRCT-lung scans were available for 172 patients, who were followed for a mean of 3.5 years, with 30 experiencing an adverse outcome.

The level of lung disease identified on the scans was graded as ‘extensive’ (>20%), ‘limited’ (<20%) or ‘indeterminate’. Those classified as ‘indeterminate’ were allocated to either extensive or limited by looking at forced vital capacity, the authors said.

“I think it’s very important to have a HRCT-lung [scan] to confirm the diagnosis of interstitial lung disease in patients with Scleroderma,” author Dr Mandana Nikpour of the University of Melbourne and St Vincent’s Hospital Melbourne told Rheumatology Update.

“What we have confirmed is that there is an added value in that enables one to prognosticate as well.”

However Dr Nikpour did not recommend serial HRCT-lung scans because of the radiation exposure and cost and said that performing serial pulmonary function tests was a better way to track changes over time.

Saying that their grading system was “simple and quick” the authors proposed “the routine use of this HRCT grading system to obtain prognostic information in patients with SSc-ILD.”

Source: Pain, C (2012), "Simple predictor in systemic sclerosis-related ILD"; Rheumatology Update; Original article can be viewed here.

 
More articles :

» arGentis Continues To Expand

But arGentis grew its drug-development pipeline this month with the acquisition of the rights to a rheumatoid arthritis therapy from the - the terms of which, were not disclosed. The treatment was developed at the University of Tennessee Health...

» Anticoagulation of Systemic Sclerosis Patients In Question

Australia is in a state of ‘clinical equipoise’ over whether to anticoagulate systemic sclerosis patients with pulmonary hypertension, experts say. And with observational studies showing the treatment is associated with a  fivefold...

» Thoracic Outlet Syndrome Secondary to Localized Scleroderma Treated With Botulinum Toxin Injection

Localized scleroderma is characterized by thickening of the skin and subcutaneous tissue. Depending on clinical and pathologic findings, localized scleroderma is classified into different subtypes: plaque morphea, generalized morphea, bullous...

» Targeting Systemic Sclerosis: From Bioinformatics to Clinical Research

Systemic sclerosis (SSc), also known as Scleroderma, is a rare autoimmune connective tissue disorder that's difficult to treat. However, thanks to new research at Dartmouth's Geisel School of Medicine and Northwestern University's Feinberg School of...

» Actelion Fibrosis Drug Doesn't Meet Key Endpoint

Actelion Ltd today announced the initial results of BUILD-3, a clinical study evaluating the safety and efficacy of Bosentan in patients suffering from idiopathic pulmonary fibrosis. While there was a consistent trend in favour of Bosentan, the...

» Bring Christmas Cheer To Someone In Hospital

Disease and trauma do not take a holiday. Many of us have loved ones in the hospital for all kinds of reasons. We want to do what we can for them, our brothers, sisters, friends, parents, children, who find themselves in strange surroundings during...